Abstract: An object of the present invention is to provide a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative disease. The present inventors have conducted intensive studies to find a compound having an inhibitory effect on NLRP3 inflammasome activation and found that an annulated pyridazine compound has an inhibitory effect on NLRP3 inflammasome activation, thus completing the present invention. The annulated pyridazine compound of the present invention is expected to serve as a prophylactic and/or therapeutic agent for inflammatory diseases and/or neurodegenerative diseases.

Abstract: The present inventors have studied and found that the substituted quinoline derivatives have acetylcholine receptor clustering-inducing action and can be useful as an active ingredient in the pharmaceutical compositions for preventing and/or treating neuromuscular diseases. The substituted quinoline derivative of the present invention may be used as an agent for preventing and/or treating neuromuscular diseases.

Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ? (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ? inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.

Abstract: An object of the present invention is to provide a pharmaceutical composition, particularly a compound suitable for preventing and/or treating an inflammatory disease and/or a neurodegenerative disease. The present inventors accomplished the present invention by conducting intensive studies to find a compound having an inhibitory effect on NLRP3 inflammasome activation, with the result that a substituted triazine compound is found to have the inhibitory effect on NLRP3 inflammasome activation. The substituted triazine compound of the present invention is expected to serve as a preventive and/or therapeutic drug for an inflammatory disease and/or a neurodegenerative disease.

Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ? (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ? inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.

Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ? (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ? inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.

Abstract: A compression device (1) includes compression portions, a suction line, connection lines, a discharge line, and display portions (d) configured to display pressure values, pressure gauges (PG1 to PG6) provided for at least one of the suction line, the connection lines, and the discharge line and a housing (40). The housing (40) includes a peripheral wall (42) and a door (44). The pressure gauges (PG1 to PG6) are situated at positions to face the door (44).

Abstract: The present application includes a compressor having a cylinder forming a compression chamber in which gas is compressed, a housing having a peripheral wall forming an internal space in which the compressor is stored, and a supporting member situated above the compressor in the internal space. The peripheral wall includes an opening wall in which a carry-out port is formed through which the cylinder is carried out. The supporting member extends to guide movement of a first lifting device between a position above the compressor and a position above the carry-out port. The cylinder is hung from the first lifting device.

Abstract: A gas supplying apparatus includes a compressor, a housing having an exhaust port, and an exhaust duct. The housing has a circumferential wall and a top wall. The circumferential wall has an access section. The exhaust port is provided on at least one of the circumferential wall and the top wall at a location higher than the access section. The exhaust duct includes a discharge port for discharging the air, exhausted from the exhaust port, to the outside. The discharge port is opened upward or opened downward in an area overlapping the top wall in an up-and-down direction.

Abstract: A system management device connected with a plurality of computation nodes includes a memory including a program instruction and a processor connected with the memory. The processor creates a list of computation nodes in which update of software is to be performed, in accordance with an input software update request, and detects a computation node in an idle state satisfying a condition for power saving, in accordance with an input power-saving operation request. When the computation node detected by the processor is on the list, the processor deactivates the detected computation node for power saving after the software thereof is updated.

Abstract: A combustible gas supply unit includes a high pressure gas facility for handling combustible gas which is compressed and a housing provided with a high pressure gas handling area containing the high pressure gas facility. The housing has a portion that is disposed in a side close to a boundary between premises of a hydrogen station and an outer region of the premises and constitutes the high pressure gas handling area, the portion being substantially composed of a partitioning wall member that resists an impact of an explosion of combustible gas.

Abstract: A compression device (1) includes compression portions, a suction line, connection lines, a discharge line, and display portions (d) configured to display pressure values, pressure gauges (PG1 to PG6) provided for at least one of the suction line, the connection lines, and the discharge line and a housing (40). The housing (40) includes a peripheral wall (42) and a door (44). The pressure gauges (PG1 to PG6) are situated at positions to face the door (44).

Abstract: The present application includes a compressor having a cylinder forming a compression chamber in which gas is compressed, a housing having a peripheral wall forming an internal space in which the compressor is stored, and a supporting member situated above the compressor in the internal space. The peripheral wall includes an opening wall in which a carry-out port is formed through which the cylinder is carried out. The supporting member extends to guide movement of a first lifting device between a position above the compressor and a position above the carry-out port. The cylinder is hung from the first lifting device.

Abstract: A system management device connected with a plurality of computation nodes includes a memory including a program instruction and a processor connected with the memory. The processor creates a list of computation nodes in which update of software is to be performed, in accordance with an input software update request, and detects a computation node in an idle state satisfying a condition for power saving, in accordance with an input power-saving operation request. When the computation node detected by the processor is on the list, the processor deactivates the detected computation node for power saving after the software thereof is updated.

Abstract: A gas supplying apparatus includes a compressor, a housing having an exhaust port, and an exhaust duct. The housing has a circumferential wall and a top wall. The circumferential wall has an access section. The exhaust port is provided on at least one of the circumferential wall and the top wall at a location higher than the access section. The exhaust duct includes a discharge port for discharging the air, exhausted from the exhaust port, to the outside. The discharge port is opened upward or opened downward in an area overlapping the top wall in an up-and-down direction.

Abstract: A combustible gas supply unit includes a high pressure gas facility for handling combustible gas which is compressed and a housing provided with a high pressure gas handling area containing the high pressure gas facility. The housing has a portion that is disposed in a side close to a boundary between premises of a hydrogen station and an outer region of the premises and constitutes the high pressure gas handling area, the portion being substantially composed of a partitioning wall member that resists an impact of an explosion of combustible gas.

Abstract: To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT5A receptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HT5A receptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.

Abstract: [Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HT5A receptor modulating action, is provided. [Means for Solution] It was confirmed that acylguanidine derivatives (the following formula I; any one of Z1, Z2, Z3, Z4 and Z5 is nitrogen atom, and the others are carbon atoms) which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline via a carbonyl group, and a cyclic group is bonded to the other ring, exhibit potent 5-HT5A receptor modulating actions and excellent pharmacological actions based on the 5-HT5A receptor modulating action, and thus can be excellent agents for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder. Thus, the present invention has been completed.

Abstract: To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT5A receptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HT5A receptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.

Abstract: [Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HT5A receptor modulating action, is provided. [Means for Solution] It was confirmed that acylguanidine derivatives (the following formula I; any one of Z1, Z2, Z3, Z4 and Z5 is nitrogen atom, and the others are carbon atoms) which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline via a carbonyl group, and a cyclic group is bonded to the other ring, exhibit potent 5-HT5A receptor modulating actions and excellent pharmacological actions based on the 5-HT5A receptor modulating action, and thus can be excellent agents for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder. Thus, the present invention has been completed.